secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001628280-25-057020
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology Q2 revenue up 11% to $15M; net income $237K, adj EBITDA $843K; positive outlook
--------------------------------------------------------------------------------

- Q2 total revenue $15.0M (+11% YoY); oncology services profit $7.8M, margin 52% vs 45%.
- Net income $237K; adjusted EBITDA $843K; prior-year net income $728K, adj. EBITDA $1.1M.
- Year-to-date revenue $29.0M (+5%); net loss $230K; adj. EBITDA $962K vs $3.2M prior.
- Cash $8.5M, no debt; management on track for full-year revenue growth and positive adj. EBITDA.
- R&D spend up 55% YoY, G&A up 57% on investments in data platform and business development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828025057020/0001628280-25-057020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828025057020/csbr-20251215.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-057020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer